Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, ...
Summary by Hastings Tribune
1 Articles
1 Articles
All
Left
Center
1
Right
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, ...
- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission rate of 73% in heavily pretreated patients with R/R T-ALL/LBL
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage